Following the April meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website. This includes the recommendations made by GMMMG in April 2025 and NICE Technology appraisals published in December 2024. A summary of approved decisions can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary and RAG list
- Bevacizumab gamma for wet age-related macular degeneration- red
- Ublituximab for relapsing remitting multiple sclerosis – red
- Terbutaline and salbutamol nebuliser solutions – green (specialist initiation)
- Spacers for use with MDIs – green
- Nicorandil – green
- Ranolazine – green (specialist advice)
- Alfacalcidol – green (specialist initiation)
- Lanthanum tablets – red for patients on dialysis, green (specialist initiation) for patients not on dialysis
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
All new and updated pathways are available at https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- GM Psoriasis and atopic dermatitis commissioning statement
- GM Pathway for primary care – PERT medicines shortage
- GM Palliative Care pain & symptom control guidelines for adults – approved; to be published once received
Colleagues are asked to disseminate for implementation within your organisations.
Items awaiting review by the ICB executive will be published once approved:
- Tirzepatide for managing overweight and obesity
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.